[A21-55] Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Addendum to Commission A20-111
Last updated 04.06.2021
Project no.:
A21-55
Commission:
Commission awarded on 28.04.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Maintenance therapy of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose tumour is associated with HRD-positive status
Patients without detectable tumour after primary surgery and patients without detectable tumour/with complete response following chemotherapy: indication of considerable added benefit.
Patients without detectable tumour after interval surgery and patients with partial response: indication of lesser benefit.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-111 | Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021.06.04 A G-BA decision was published.